The present invention discloses novel proinsulin glargine and method for for preparing insulin glargine therefrom. A sequence of the proinsulin glargine containing SOD fusion peptide subjected to site-directed mutagenesis and “0 C peptide” is designed; recombinant Escherichia coli for expressing insulin glargine are constructed; insulin glargine fusion protein in a form of an inclusion body is expressed; and denaturation, renaturation, modification, enzyme digestion, separation and purification are carried out to obtain a mature insulin glargine active pharmaceutical ingredient. According to the present invention, the SOD fusion peptide sequence is mutated to enhance the fermentation yield of the insulin glargine by 75%; and a “0 C peptide” strategy is adopted to reduce the quality loss and miscleavage impurities in the enzyme digestion transformation. The purity of the insulin glargine active pharmaceutical ingredient prepared in the present invention is up to 99.9%, and the maximum single impurity content is controlled at 0.05%.

The present disclosure pertains to compositions comprising anti-VEGF proteins.

Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.

The present disclosure pertains to compositions comprising anti-VEGF proteins.

Provided herein are methods, reagents, and kits for isolating polypeptides, such as a proteome. Also provided herein is a modified trypsin polypeptide that is resistant to autolysis, and that can be selectively-separated from a biological sample once digestion is complete.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for administering such compositions.

The present invention discloses monodisperse protein-dendron conjugates that self-assemble to generation-dependent supramolecular protein assemblies of different size and surface charges. The invention further provides a process for synthesis of protein-dendron conjugates containing hydrophobic dendron of different generations.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Pandemic COVID 19 causes global crisis in human health and economy. The pathogen of COVID 19, like the Influenzas causing common flus, belongs to a common type of virus called Ribonucleic Acid (RNA) virus. RNA viruses are composed of three structural components: genomic RNA, envelop and nuclear proteins, and bilayer lipid membrane. Targeting COVID 19 and all RNA viruses, the present invention describes an effective disinfectant system, which applies the combination of RNases, proteases, and detergents, at a broad range of concentration, pH, and temperature in the utilization, to eliminate the RNA viruses from any contaminated surfaces, airways, and filters. The disinfectant system provides an effective, convenient, environment friendly, and safe solution, for commercial and customer use, to disinfect RNA virus pathogens in concern.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.